GlassScriptPhysician profile
Carol Ann Menner
NPI 1922019181
$2,015.05
in general payments reported to CMS, 2019-2025
12 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $159 · 2021: $103 · 2022: $500 · 2023: $390 · 2024: $253 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,047.71 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $251.64 | 2022-2025 | Miebo, Xiidra |
| Genentech USA, INC. | $242.19 | 2019-2024 | Vabysmo |
| Allergan, INC. | $90.00 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $80.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.86 | 2020-2022 | |
| Abbvie INC. | $61.67 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $47.12 | 2020 | |
| Apellis Pharmaceuticals, INC. | $44.47 | 2023-2025 | Syfovre |
| Alimera Sciences, INC. | $29.69 | 2024 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $20.49 | 2024 | |
| Vyera Pharmaceuticals, LLC | $19.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Menner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.